Philip S. Low
Next Generation Targeted Therapeutics
Lab Members
Philip Low
Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low has spent over 50 years exploring:
- targeted therapeutic and imaging agents for multiple human diseases (including cancer, autoimmune, infectious, inherited, and inflammatory diseases),
- the structure, function, and pathologies of the erythrocyte membrane, and
- signal transduction across plant cell membranes.
He has published over 500 scientific articles and has over 360 US patents/patents pending. Eight drugs stemming from his research are undergoing human clinical trials and seven companies (Endocyte Inc., OnTarget Laboratories Inc., Quince Therapeutics Inc., Umoja Biopharma, Eradivir Inc., Morphimmune Inc., and ErythroCure Inc.) have been founded to commercialize these discoveries. Dr. Low received his B.S. in Chemistry from BYU (1971) and his Ph.D. in Biochemistry from UCSD (1975).
Email: plow@purdue.edu
Staff
|
Madduri Srinivasarao Lab Manager |
Charity Lynn Campbell Laboratory Technician |
Patricia Cauble Administrative Assistant |
Group Members
Visiting Scholars
|
Ananada Kumar Kanduluru Visiting Scholar
|
Fenghua Zhang Visiting Scholar Design and preclinical testing of targeted immunotherapies for fibrotic diseases that act by selectively reprogramming profibrotic M2-like macrophages to antifibrotic M1-like macrophages. |
Haiyan Chu Visiting Scholar |
|
Spencer Dirk Lindeman Visiting Scholar Drug design, synthesis, preclinical evaluation, and development of radioligand imaging and therapy agents for cancer, as well as immunomodulation of additional diseases such as fibrosis and inflammation. |
|
|
Post-Doctorates
|
Anqi Zhang Post-Doctorate |
John Victor Napoleon Post-Doctorate |
Mahesh Kumar Rao Yelineni Post-Doctorate |
|
Mohini Kamra Post-Doctorate
|
Rajeswara Reddy Mannem Post-Doctorate
|
Ramesh Mukkamla Post-Doctorate Design and development of Fibroblast Activation Protein (FAP) targeted ligands and their applications for delivery of attached imaging and therapeutic agents to cancers and fibrotic diseases. |
|
Reuben Dass Post-Doctorate
|
Sagnik Sengupta Post-Doctorate |
Seth Herr Post-Doctorate |
|
Shivakrishna Kallepu Post-Doctorate
|
Sudarshan Reddy Kasireddy Post-Doctorate Design and synthesis of ligand-targeted microRNAs for the selective modulation of gene expression in cancer cells in vivo.
|
Suilan Zheng Post-Doctorate Design of novel CAR T cell (Chimeric Antigen Receptor T cell) based immunotherapies for solid tumors that can be sensitively and continuously regulated following their infusion into cancer patients. |
|
Suresh Yarlagadda Post-Doctorate |
Graduate Students
|
Bo Huang Ph.D. graduate student
|
Charles Key Stone Ph.D. Graduate Student
|
Christopher Jensen Ph.D. graduate student Development of applications for steroids targeted to activated macrophages in the treatment of autoimmune and inflammatory diseases. |
|
Da Sol Jung Ph.D. graduate student Development of targeted chemo- and radiotherapeutic agents that accumulate specifically in bone metastases and eradicate the painful lesions without causing damage to healthy tissues.
|
Imrul Shahriar Ph.D. graduate student Development of bispecific small molecules that can form a bridge between a virus-infected cell and an immune effector cell leading to eradication of the viral infection. I am keenly interested in applying the principles of molecular modelling, virology and immunology to curing life-threatening viral infections. |
Jacob David Newey Ph.D. Graduate Student
|
|
Kavya Ananthaswamy Ph.D. Graduate Student
|
Mohammed Sazzadul Bari Ph.D. Graduate Student
|
Mohammed Yusuf Al Amin Ph.D. Graduate Student Development of cytokine inhibitory drugs targeting (a) tumor associated macrophages (TAMs) and cancer associated fibroblasts (CAFs) in the management of cancer, and (b) activated macrophages and fibroblasts in the treatment of fibrosis. |
|
Shomoita Sayed Ph.D. Graduate Student |
Yingqi Chen Ph.D. Graduate Student |
|
